|
PRKACB expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.40167910401124E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.96890004300343E-09 |
| Normal-vs-Stage2 |
3.461800E-01 |
| Normal-vs-Stage3 |
2.08719996841467E-09 |
| Normal-vs-Stage4 |
1.62458935193399E-12 |
| Stage1-vs-Stage2 |
2.437800E-02 |
| Stage1-vs-Stage3 |
2.000200E-01 |
| Stage1-vs-Stage4 |
7.9620000000058E-05 |
| Stage2-vs-Stage3 |
3.375500E-03 |
| Stage2-vs-Stage4 |
7.50260000000891E-05 |
| Stage3-vs-Stage4 |
5.885600E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.6278089987054E-12 |
| Normal-vs-AfricanAmerican |
9.913400E-01 |
| Normal-vs-Asian |
5.33617594555835E-12 |
| Caucasian-vs-AfricanAmerican |
1.478390E-01 |
| Caucasian-vs-Asian |
6.964800E-01 |
| AfricanAmerican-vs-Asian |
1.313820E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.93470000523044E-08 |
| Normal-vs-Female |
6.50739462315642E-11 |
| Male-vs-Female |
8.103200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
9.00379770740756E-12 |
| Normal-vs-Age(41-60Yrs) |
1.1060996563117E-10 |
| Normal-vs-Age(61-80Yrs) |
2.112000E-02 |
| Normal-vs-Age(81-100Yrs) |
1.221370E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.890000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.351990E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.233200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.045800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.328800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.110000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.87379999978022E-07 |
| Classical-VS-Follicular |
5.76839997989964E-09 |
| Classical-VS-Other |
1.078950E-01 |
| Classical-VS-Normal |
1.65578661892596E-12 |
| Tall-VS-Follicular |
1.6752155218569E-12 |
| Tall-VS-Other |
1.799350E-01 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
1.70950000000225E-06 |
| Follicular-VS-Normal |
8.362800E-01 |
| Other-VS-Normal |
4.04170000023463E-07 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.638120E-04 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
3.94479999998865E-07 |
|
|
